Quantcast
Home > Quotes > DFFN

Diffusion Pharmaceuticals Inc. Common Stock (DFFN) Quote & Summary Data

DFFN 
$2.4
*  
0.11
4.8%
Get DFFN Alerts
*Delayed - data as of Jul. 17, 2019  -  Find a broker to begin trading DFFN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    DFFN After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.36 / $ 2.45
1 Year Target
10
Today's High / Low
$ 2.41 / $ 2.2412
Share Volume
151,879
50 Day Avg. Daily Volume
145,008
Previous Close
$ 2.29
52 Week High / Low
$ 11 / $ 1.83
Market Cap
11,271,372
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.05

Intraday Chart

Shares Traded

Share Volume:
151,879
50 Day Avg. Daily Volume:
145,008

Trading Range

The current last sale of $2.40 is 31.15% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.41 $ 11
 Low: $ 2.2412 $ 1.83

Company Description (as filed with the SEC)

We are a clinical stage biotechnology company developing new treatments for life threatening conditions by improving the body's ability to bring oxygen to the areas where it is needed most. We are developing our lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate ("TSC"), for use in those life threatening conditions in which cellular oxygen deprivation ("hypoxia") is the basis for significant unmet medical needs. TSC is designed to safely and selectively target and re-oxygenate the micro-environment of hypoxic cells, and potentially be used in many indications, including oncology and cardiovascular/stroke. In cancer, TSC re-oxygenates treatment-resistant cancerous tissue, making the cancer cells up to three times more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy.  ... More ...  



Risk Grade

Where does DFFN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.30
Open Date:
Jul. 17, 2019
Close Price:
$ 2.36
Close Date:
Jul. 17, 2019


Consensus Recommendation

Analyst Info